Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionRegions Financial Corp
Latest Disclosed Ownership2,681 shares
Latest Disclosed Value $ 353,195
Regions Financial Corp reports 5.16% decrease in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 5, 2026 - Regions Financial Corp filed a 13F-HR form disclosing ownership of 2,681 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $353,195 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 27, 2026 disclosing 2,827 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -5.16% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,681 -146 -5.16 353 -11.75 0.0023
2026-01-27 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,827 238 9.19 401 10.19 0.0026
2025-11-19 2025-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 2,589 6 0.23 363 12.04 0.0024
2025-11-19 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,589 6 363 0.0023
2025-07-29 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,583 -106 -3.94 325 9.09 0.0022
2025-05-08 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,689 100 3.86 297 -15.86 0.0022
2025-02-14 2024-12-31 13F Neurocrine Biosciences COM 64125C109 2,589 -35 -1.33 353 16.89 0.0026
2024-11-14 2024-09-30 13F Neurocrine Biosciences COM 64125C109 2,624 -543 -17.15 302 -30.73 0.0022
2024-07-31 2024-06-30 13F Neurocrine Biosciences COM 64125C109 3,167 -18 -0.57 436 -0.68 0.0033
2024-04-23 2024-03-31 13F Neurocrine Biosciences COM 64125C109 3,185 -155 -4.64 439 -0.23 0.0033
2024-02-06 2023-12-31 13F Neurocrine Biosciences COM 64125C109 3,340 -125 -3.61 440 13.11 0.0036
2023-11-01 2023-09-30 13F Neurocrine Biosciences COM 64125C109 3,465 -120 -3.35 390 15.09 0.0035
2023-08-09 2023-06-30 13F Neurocrine Biosciences COM 64125C109 3,585 -69 -1.89 338 0.0029
2023-05-12 2023-03-31 13F Neurocrine Biosciences COM 64125C109 3,654 -215 -5.56 0 0.0033
2023-02-06 2022-12-31 13F Neurocrine Biosciences COM 64125C109 3,869 -50 -1.28 0 -100.00 0.0042
2022-11-03 2022-09-30 13F Neurocrine Biosciences COM 64125C109 3,919 -168 -4.11 416 4.52 0.0042
2022-07-25 2022-06-30 13F Neurocrine Biosciences COM 64125C109 4,087 484 13.43 398 17.75 0.0038
2022-04-25 2022-03-31 13F Neurocrine Biosciences COM 64125C109 3,603 877 32.17 338 45.69 0.0027
2022-01-31 2021-12-31 13F Neurocrine Biosciences COM 64125C109 2,726 -434 -13.73 232 -23.43 0.0018
2021-11-04 2021-09-30 13F Neurocrine Biosciences COM 64125C109 3,160 70 2.27 303 0.66 0.0026
2021-07-27 2021-06-30 13F Neurocrine Biosciences COM 64125C109 3,090 -1,412 -31.36 301 -31.12 0.0026
2021-06-02 2021-03-31 13F Neurocrine Biosciences COM 64125C109 4,502 63 1.42 437 2.82 0.0040
2021-02-05 2020-12-31 13F Neurocrine Biosciences COM 64125C109 4,439 -18 -0.40 425 -0.93 0.0041
2020-10-15 2020-09-30 13F Neurocrine Biosciences COM 64125C109 4,457 1 0.02 429 -21.14 0.0047
2020-07-27 2020-06-30 13F Neurocrine Biosciences COM 64125C109 4,456 1,055 31.02 544 84.41 0.0063
2020-04-29 2020-03-31 13F Neurocrine Biosciences COM 64125C109 3,401 307 9.92 295 -11.41 0.0039
2020-02-03 2019-12-31 13F Neurocrine Biosciences COM 64125C109 3,094 60 1.98 333 21.98 0.0035
2019-10-24 2019-09-30 13F Neurocrine Biosciences COM 64125C109 3,034 -33 -1.08 273 5.41 0.0030
2019-07-19 2019-06-30 13F Neurocrine Biosciences COM 64125C109 3,067 90 3.02 259 -1.15 0.0029
2019-04-19 2019-03-31 13F Neurocrine Biosciences COM 64125C109 2,977 688 30.06 262 59.76 0.0030
2019-01-28 2018-12-31 13F Neurocrine Biosciences COM 64125C109 2,289 1,005 78.27 164 3.80 0.0020
2018-10-22 2018-09-30 13F Neurocrine Biosciences COM 64125C109 1,284 -10 -0.77 158 24.41 0.0017
2018-07-26 2018-06-30 13F Neurocrine Biosciences COM 64125C109 1,294 1,294 127 0.0014
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.